e-learning
resources
European Respiratory Review
2017
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Pharmacotherapy for idiopathic pulmonary fibrosis: current landscape and future potential
Ganesh Raghu
Source:
Eur Respir Rev, 26 (145) 170071; 10.1183/16000617.0071-2017
Journal Issue:
September
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Ganesh Raghu. Pharmacotherapy for idiopathic pulmonary fibrosis: current landscape and future potential. Eur Respir Rev, 26 (145) 170071; 10.1183/16000617.0071-2017
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Idiopathic pulmonary fibrosis: present understanding and future options
Source: Eur Respir Rev 2011; 20: 132-133
Year: 2011
Idiopathic pulmonary fibrosis: current challenges and future perspectives
Source: Eur Respir Rev 2013; 22: 103-105
Year: 2013
Current and future therapeutic approaches in idiopathic pulmonary fibrosis
Source: Eur Respir J 2005; 26: 693-703
Year: 2005
The changing treatment landscape in idiopathic pulmonary fibrosis
Source: Eur Respir Rev 2015; 24: 65-68
Year: 2015
A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials
Source: Eur Respir J 2015; 46: 243-249
Year: 2015
Potential new biomarkers for idiopathic pulmonary fibrosis
Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis
Year: 2020
PROFILEing idiopathic pulmonary fibrosis: rethinking biomarker discovery
Source: Eur Respir Rev 2013; 22: 148-152
Year: 2013
The 2015 guidelines for idiopathic pulmonary fibrosis: an important chapter in the evolution of the management of patients with IPF
Source: Eur Respir J 2015; 46: 883-886
Year: 2015
Staging of idiopathic pulmonary fibrosis: past, present and future
Source: Eur Respir Rev 2014; 23:220-224
Year: 2014
Where do we go from here? Clinical drug development in idiopathic pulmonary fibrosis
Source: Eur Respir J 2015; 45: 1218-1220
Year: 2015
The therapy of idiopathic pulmonary fibrosis: what is next?
Source: Eur Respir Rev, 28 (153) 190021; 10.1183/16000617.0021-2019
Year: 2019
Idiopathic pulmonary fibrosis: recent milestones in disease management
Source: Eur Respir Rev 2012; 21: 140
Year: 2012
Historical eye on idiopathic pulmonary fibrosis: redefining the mortality scenario.
Source: Virtual Congress 2020 – New clinical insights into idiopathic pulmonary fibrosis
Year: 2020
Idiopathic pulmonary fibrosis: another step in understanding the burden of this disease
Source: Eur Respir J 2016; 48: 26-28
Year: 2016
Pirfenidone treatment in idiopathic pulmonary fibrosis: too much of a great expectation
Source: Eur Respir J 2012; 40: 794-795
Year: 2012
Idiopathic pulmonary fibrosis: treatment options in pursuit of evidence-based approaches
Source: Eur Respir J 2006; 28: 463-465
Year: 2006
Best supportive care for idiopathic pulmonary fibrosis: current gaps and future directions
Source: Eur Respir Rev, 27 (147) 170076; 10.1183/16000617.0076-2017
Year: 2018
Sildenafil for pulmonary hypertension complicating idiopathic pulmonary fibrosis: a rationale grounded in basic science
Source: Eur Respir J 2016; 47:1615-1617
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept